Pfizer Inc. (FRA:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 116.63B |
| Revenue (ttm) | 54.48B |
| Net Income (ttm) | 9.18B |
| Shares Out | n/a |
| EPS (ttm) | 1.62 |
| PE Ratio | 12.71 |
| Forward PE | 8.64 |
| Dividend | 1.55 (7.54%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 6,780 |
| Average Volume | 55,727 |
| Open | 20.52 |
| Previous Close | 20.49 |
| Day's Range | 20.29 - 20.57 |
| 52-Week Range | 18.57 - 27.77 |
| Beta | n/a |
| RSI | 40.33 |
| Earnings Date | Nov 4, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.
Where Will Pfizer Be in 5 Years?
The pharma giant may be heading for a new era of growth.
Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?
Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).
METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale Met...
Can PFE Successfully Return to the Obesity Space With Metsera Buyout?
Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.
PFE Quantitative Stock Analysis
Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy of Me...
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpo...
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, ...
This Hated Stock Suddenly Looks Like an Obesity Bargain
Pfizer's latest deal could make it the budget entry point to the weight-loss bonanza.
This Hated Stock Suddenly Looks Like an Obesity Bargain
Pfizer's latest deal could make it the budget entry point to the weight-loss bonanza.
Company News for Sep 23, 2025
Companies In The News Are: ORCL, TAP, AAPL, MTSR, PFE.
3 High-Yielding Dividend Stocks to Buy and Hold for the Long Haul -- Including United Parcel Service (UPS) and Pfizer
Each of these dividend payers sports a fat yield of more than 6.5%.
What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?
Key PointsPfizer will acquire Metsera in a deal worth $4.9 billion up front and up to $7.3 billion if the acquired assets succeed further.
Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market
In an unrelenting quest for blockbuster potential in drugs, Pfizer Inc. announced on September 22, 2025, its deal to acquire Metsera, a groundbreaking biotech company that focuses on state-of-the-art ...
Viking Therapeutics: Oral Study Disappoints, Competitor Gets Bought Out (Rating Downgrade)
Read here to get insights on Viking (VKTX) stock's phase 3 obesity drug trial, its promising results, and why Pfizer chose a rival.
Final Trade: AAPL, C, PFE, KVUE
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Market Today: Pfizer Eyes Metsera Acquisition Amid Broad Market Moves
Market Today: Pfizer Eyes Metsera Acquisition Amid Broad Market Moves
Final Trade: AAPL, C, PFE, KVUE
The final trades of the day with CNBCs Melissa Lee and the Fast Money traders.
Metsera: Long-Acting MET-097i And Product Differentiation Nets Pfizer Acquisition
Metsera, Inc. is being acquired by Pfizer Inc. for up to $7.3 billion, driven by its innovative obesity drug pipeline. Click to read why MTSR is a Strong Buy.
Pfizer just paid a lot of cash to catch up in the GLP race. Why its stock is higher
Pfizer is spending more than $7 billion to buy biotech Metsera to try to catch cup in the obesity drug market.
Tim Seymour on the stock market and Pfizer deal
Tim Seymour, founder and CIO of Seymour Asset Management, discusses his view on the market after the Fed cut rates for the first time in 2025.
Pfizer (PFE) Stock Rises on Acquisition News
Pfizer (PFE) Stock Rises on Acquisition News
Pfizer bets $7.3 billion on obesity drugs with Metsera buy
Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications fo...
BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity
Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'The Exchange' to discuss Pfizer's obesity drug prospects, competitors and much more.
Pfizer Inc. (PFE) Discusses On Proposed Acquisition Of Metsera, Inc. Call (Transcript)
Pfizer acquires Metsera to expand its next-gen obesity portfolio with innovative, long